KV Pharmaceutical (KV.A)
KV Pharmaceutical Revenues: 5.10M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
KV.A Revenues Rankings
| Overall | 7th percentile | 4097 of 4432 |
| Sector | 24th percentile | 353 of 470 in Healthcare |
| Industry | 36th percentile | 7 of 11 in Drug Delivery & Accessories |
KV.A Revenues Range, Past 5 Years
| Minimum | -176.62M | Mar 2009 |
| Maximum | 171.18M | Sep 2007 |
| Average | 39.10M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these KV.A related companies
KV.A News
$KVA ahhhh yes the Vol everyone was wondering about hmm, Cheers!
about 5 days ago by HighGrowthFinancial
about 5 days ago by HighGrowthFinancial
RT @HighGrowthFinancial after seeing $PPHM bounce today, $KVA is gettting some attention, downside shrinking
about 5 days ago by HighGrowthFinancial
about 5 days ago by HighGrowthFinancial
$KVA having trouble staying red, I noted seller's tired few days ago
about 6 days ago by HighGrowthFinancial
about 6 days ago by HighGrowthFinancial
$PPHM holding recent gains ok,called $KVA out off there strength few days ago,great companies now risky,Horrible companies working LONG
about 6 days ago by HighGrowthFinancial
about 6 days ago by HighGrowthFinancial
after seeing $PPHM bounce today, $KVA is gettting some attention, downside shrinking
about 9 days ago by HighGrowthFinancial
about 9 days ago by HighGrowthFinancial
@unusual7 Up/down on $KVA. Down on day traders, keep selling & make the stock worth less. $KVA is crap shoot IMO worth it. Long time holder.
about 13 days ago by Greg434
about 13 days ago by Greg434
$KV.A Greg how do u know this? Werent u negativ about KVA b4 asking whats happening?
about 13 days ago by unusual7
about 13 days ago by unusual7
$KV.A is a long term play. June 2012 could show healthy gains. If your in, stay in. If you not, get in. Rewards coming very soon.
about 14 days ago by Greg434
about 14 days ago by Greg434
$KV.A Oh, i bought @ 2.90 so will it ever go above that again? And why did it even go pass 3.00last Feb?
about 16 days ago by unusual7
about 16 days ago by unusual7
$KV.A @unusual7 If I had to guess, some one had something to gain by lying. Buy low, upgrade to buy, sell after spike. Theives run market.
about 16 days ago by Greg434
about 16 days ago by Greg434
$KV.A Ya, I want to know why they rated this stock a buy@ & gave a price target of $5.00???!!!! I'm about to lose all my$!
about 16 days ago by unusual7
about 16 days ago by unusual7
$KV.A - Anyone know why KVA is taking such a beating today? Or is the the fact that CEO Greg Divis hasn't yet been replaced.
about 19 days ago by Greg434
about 19 days ago by Greg434
Scott+Scott LLP Alert: Impending Deadline in K-V Pharmaceutical Company Securities Class Action -- KV-A and KV-B
Dec 12, 7:22PM GlobeNewswire
Dec 12, 7:22PM GlobeNewswire
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against K-V Pharmaceutical Company
Nov 02, 9:40PM Business Wire
Nov 02, 9:40PM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KV.A | 1.18 | -0.04 | -3.28% | 73.05M |
| KUTV | 1.26 | -0.07 | -5.26% | 46.30M |
| KUN | 0.1428 | +0.00 | +0.00% | 2.810M |
| KUB | 41.97 | +0.05 | +0.12% | 10.53B |
| KTOS | 5.395 | -0.14 | -2.44% | 179.61M |
| KTF | 14.36 | +0.08 | +0.56% | |
| KTEC | 9.75 | -0.19 | -1.91% | 53.18M |
| KTCC | 10.51 | -0.21 | -1.96% | 112.02M |
| KT | 11.73 | -0.11 | -0.93% | 5.761B |
| KSWS | 2.76 | +0.01 | +0.36% | 97.90M |
